Treatment of Parkinson’s disease with piribedil: Suggestions for clinical practices
Advanced Neurology · 2023
DOI: 10.36922/an.290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Neurology, 2023. Verfasst von Cheng Jie Mao und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
With rapidly growing rates of prevalence, disability, and mortality, Parkinson’s disease (PD) has become a global healthcare burden. Increasing elderly population increases the incidence of neurodegenerative diseases in China. Hence, PD poses a huge burden to Chinese economic and healthcare system. PD is a movement disorder that affects the motor and nonmotor functions. Dopamine agonists are used in the management of PD. Piribedil is an antiparkinsonian drug and piperazine derivative, which acts as D2/D3 receptor agonist. Piribedil is one of the non-ergot dopamine receptor (DR) agonists and has been used in China for many years as monotherapy or in combination with levodopa. In this paper, we present a review of clinical application of piribedil, management of adverse events, and drug interactions, and discuss the results of clinical trials of piribedil on motor and non-motor symptoms of PD.
Zitieren
APA
Mao, C. J., Piu, C., Jin, L. R., Wang, L. J., Rascol, O., & Liu, C. F. (2023). Treatment of Parkinson’s disease with piribedil: Suggestions for clinical practices. Advanced Neurology. https://doi.org/10.36922/an.290
Vancouver
Mao CJ, Piu C, Jin LR, Wang LJ, Rascol O, Liu CF. Treatment of Parkinson’s disease with piribedil: Suggestions for clinical practices. Advanced Neurology. 2023. doi:10.36922/an.290
BibTeX
@article{Mao2023,
author = {Mao, Cheng Jie and Piu, Chan and Jin, Li Rong and Wang, Li Juan and Rascol, Olivier and Liu, Chun Feng},
title = {Treatment of Parkinson’s disease with piribedil: Suggestions for clinical practices},
journal = {Advanced Neurology},
year = {2023},
doi = {10.36922/an.290}
}
EUVIMED